Overview
I first became interested in clinical immunology as a medical student studying autoimmune inflammatory eye disease at the National Institutes of Health. Since then, I have been inspired to understand what causes autoimmunity and immune deficiency disorders in order to improve the quality of life for my patients. I see patients with multiple complex immune disorders with particular expertise in autoimmune and Rheumatoid arthritis, primary Sjogren's syndrome, and the immunodeficiency disorders Common Variable Immunodeficiency (CVID), Adenosine Deaminase Deficiency (ADA) disorders, and WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis). My research investigates immune targets that may impact either the development of immune disease or identify new therapies for patients. The goal is to help us understand why and how immunologic diseases develop so that we may better treat them.
Current Appointments & Affiliations
In the News
View All News
Recent Publications
Early identification of delayed-onset ADA deficiency: The case for expanded first-tier newborn screening
Journal Article Journal of Human Immunity · January 5, 2026 Standard newborn screening using T cell receptor excision circles (TRECs) failed to detect delayed-onset ADA deficiency in two cases. Retrospective mass spectrometry (MS/MS) analysis showed diagnostic deoxyadenosine elevation at birth. We advocate ... Full text CiteClinicopathologic Features and the Spectrum of Myelokathexis in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Syndrome.
Journal Article Lab Invest · August 2025 Warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome is a rare primary immunodeficiency disorder predominantly caused by germline CXCR4 variants. Bone marrow (BM) evaluation showing myelokathexis helps to establish the diagnosis of WHIM ... Full text Link to item CiteComment on: Use of Plerixafor for Short-Term Management of Leukopenia in a Pediatric Patient With WHIM Syndrome.
Journal Article Pediatr Blood Cancer · July 2025 Full text Link to item CiteRecent Grants
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infec
Clinical TrialPrincipal Investigator · Awarded by X4 Pharmaceuticals · 2025 - 2029Deconstructing the molecular and cellular mechanisms of psoriatic arthritis pain by an improved animal model
ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2028HZNP-DAZ-303: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Dazodalibep in participants with Sjogren's syndrome with moderate-to-severe symptom state.
Clinical TrialPrincipal Investigator · Awarded by Horizon Therapeutics Ireland DAC · 2024 - 2026View All Grants